Menu
← Oncology Approval Tracker
FDA DECISION ·
Hercessi
trastuzumab-strf · Accord BioPharma
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Trastuzumab biosimilar for labeled HER2-overexpressing adjuvant and metastatic breast cancer uses and first-line metastatic gastric or gastroesophageal junction adenocarcinoma with designated chemotherapy.
LAMPGEN ANALYSIS
Why it matters
The biosimilar adds another IV trastuzumab supply option for established HER2-positive indications.
What research teams should watch
Retain the HER2 diagnostic result and standardize cardiac monitoring and product traceability across ordering and dispensing.
PRIMARY RECORDS